MIFH
GLUE icon

Migdal Insurance & Financial Holdings’s Monte Rosa Therapeutics GLUE Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-124
Closed -$3K – 640
2021
Q4 		$3K Sell
124
-126
-50% -$2.64K ﹤0.01% 661
2021
Q3 		$6K Buy
+250
New +$7.17K ﹤0.01% 628

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings's GLUE Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Monte Rosa Therapeutics (GLUE) in Q1 2022, closing a stake of 124 shares — an estimated $3K sold.

Migdal Insurance & Financial Holdings first reported a position in GLUE in Q3 2021 and held it in 2 quarters. The position peaked at $6K in Q3 2021. 52 funds tracked by Wall St. Rank hold GLUE as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Monte Rosa Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 124 Monte Rosa Therapeutics shares in Q1 2022, an estimated $3K.
  • Migdal Insurance & Financial Holdings first reported a position in Monte Rosa Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Monte Rosa Therapeutics position peaked at $6K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.